Literature DB >> 24241346

PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients.

Wei-feng Wang1, Yan Xie, Zhi-hua Zhou, Zheng-hong Qin, Jun-chao Wu, Jing-kang He.   

Abstract

AIM: To investigate the role of PIK3CA oncogene in tumorigenesis and development of esophageal cancer in Chinese patients at the levels of genetic mutation and epigenetics.
METHODS: Seventy six esophageal tumor samples and corresponding adjacent normal tissues were collected, and the genomic DNA was extracted. Mutations in the 9th and 20th exons of PIK3CA gene were detected using conventional sequencing. PIK3CA methylation rates in two selected CpG islands (CpG island 1 and 2) were detected using sub-bisulfate modified sequencing. P110α and pAKT expression levels were detected with Western blotting.
RESULTS: In PIK3CA gene of the tumor tissues, G1633C (E545Q) mutation was detected in the 9th exon with a rate of 3.95% (3/76), whereas mutation was not found in the 20th exon. Nor mutation did occur in PIK3CA gene of the adjacent normal tissues. The methylation rate of the CpG island 1 had no significant difference between the tumor and adjacent tissues (0.77%±0.009% vs 0.89%±0.008%), but the methylation rate of the CpG island 2 in the esophageal tumors was significantly lower than that in the adjacent tissues (6.00%±2.80% vs 10.45%±5.51%). Furthermore, the rate of methylation of the CpG island 2 in TNM stage III and IV esophageal cancer (3.84%±2.08%) was significantly lower than in stage I (8.52%±2.55%) and stage II (6.42%±2.36%). PIK3CA gene hypomethylation in esophageal cancer was significantly correlated with high expression of p110α.
CONCLUSION: PIK3CA gene hypomethylation plays a key role in the tumorigenesis and development of esophageal cancer in Chinese patients, while the mutations of PIK3CA gene have little effect on the development of esophageal cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24241346      PMCID: PMC4002570          DOI: 10.1038/aps.2013.163

Source DB:  PubMed          Journal:  Acta Pharmacol Sin        ISSN: 1671-4083            Impact factor:   6.150


  39 in total

1.  PIK3CA mutations in advanced ovarian carcinomas.

Authors:  Yun Wang; Aslaug Helland; Ruth Holm; Gunnar B Kristensen; Anne-Lise Børresen-Dale
Journal:  Hum Mutat       Date:  2005-03       Impact factor: 4.878

2.  Frequent mutation of the PIK3CA gene in ovarian and breast cancers.

Authors:  Douglas A Levine; Faina Bogomolniy; Cindy J Yee; Alex Lash; Richard R Barakat; Patrick I Borgen; Jeff Boyd
Journal:  Clin Cancer Res       Date:  2005-04-15       Impact factor: 12.531

3.  PIK3CA mutations in glioblastoma multiforme.

Authors:  Christian Hartmann; Gesine Bartels; Claire Gehlhaar; Nikola Holtkamp; Andreas von Deimling
Journal:  Acta Neuropathol       Date:  2005-05-28       Impact factor: 17.088

4.  PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas.

Authors:  Jong Woo Lee; Young Hwa Soung; Su Young Kim; Hae Woo Lee; Won Sang Park; Suk Woo Nam; Sang Ho Kim; Jung Young Lee; Nam Jin Yoo; Sug Hyung Lee
Journal:  Oncogene       Date:  2005-02-17       Impact factor: 9.867

5.  Mutation of the PIK3CA gene in ovarian and breast cancer.

Authors:  Ian G Campbell; Sarah E Russell; David Y H Choong; Karen G Montgomery; Marianne L Ciavarella; Christine S F Hooi; Briony E Cristiano; Richard B Pearson; Wayne A Phillips
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

6.  PIK3CA alterations in primary (de novo) and secondary glioblastomas.

Authors:  Daisuke Kita; Yasuhiro Yonekawa; Michael Weller; Hiroko Ohgaki
Journal:  Acta Neuropathol       Date:  2007-01-18       Impact factor: 17.088

7.  PIK3CA cooperates with other phosphatidylinositol 3'-kinase pathway mutations to effect oncogenic transformation.

Authors:  Katsutoshi Oda; Jennifer Okada; Luika Timmerman; Pablo Rodriguez-Viciana; David Stokoe; Keiko Shoji; Yuji Taketani; Hiroyuki Kuramoto; Zachary A Knight; Kevan M Shokat; Frank McCormick
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

8.  Oncogenic mutations of PIK3CA in human cancers.

Authors:  Yardena Samuels; Victor E Velculescu
Journal:  Cell Cycle       Date:  2004-10-12       Impact factor: 4.534

9.  PIK3CA mutations and copy number gains in human lung cancers.

Authors:  Hiromasa Yamamoto; Hisayuki Shigematsu; Masaharu Nomura; William W Lockwood; Mitsuo Sato; Naoki Okumura; Junichi Soh; Makoto Suzuki; Ignacio I Wistuba; Kwun M Fong; Huei Lee; Shinichi Toyooka; Hiroshi Date; Wan L Lam; John D Minna; Adi F Gazdar
Journal:  Cancer Res       Date:  2008-09-01       Impact factor: 12.701

10.  Mutations of PIK3CA in gastric adenocarcinoma.

Authors:  Vivian Sze Wing Li; Chi Wai Wong; Tsun Leung Chan; Agnes Sze Wah Chan; Wei Zhao; Kent-Man Chu; Samuel So; Xin Chen; Siu Tsan Yuen; Suet Yi Leung
Journal:  BMC Cancer       Date:  2005-03-23       Impact factor: 4.430

View more
  9 in total

1.  Psoralidin inhibits proliferation and enhances apoptosis of human esophageal carcinoma cells via NF-κB and PI3K/Akt signaling pathways.

Authors:  Zhiliang Jin; Wei Yan; Hui Jin; Changzheng Ge; Yanhua Xu
Journal:  Oncol Lett       Date:  2016-06-15       Impact factor: 2.967

2.  PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma.

Authors:  Shi-Yuan Liu; Wei Chen; Ehtesham Annait Chughtai; Zhe Qiao; Jian-Tao Jiang; Shao-Min Li; Wei Zhang; Jin Zhang
Journal:  World J Gastroenterol       Date:  2017-04-14       Impact factor: 5.742

3.  Up-Regulation of PI 3-Kinases and the Activation of PI3K-Akt Signaling Pathway in Cancer Stem-Like Cells Through DNA Hypomethylation Mediated by the Cancer Microenvironment.

Authors:  Aung Ko Ko Oo; Anna Sanchez Calle; Neha Nair; Hafizah Mahmud; Arun Vaidyanath; Junya Yamauchi; Aprilliana Cahya Khayrani; Juan Du; Md Jahangir Alam; Akimasa Seno; Akifumi Mizutani; Hiroshi Murakami; Yoshiaki Iwasaki; Ling Chen; Tomonari Kasai; Masaharu Seno
Journal:  Transl Oncol       Date:  2018-04-02       Impact factor: 4.243

4.  PIK3CA mutation is a favorable prognostic factor in esophageal cancer: molecular profile by next-generation sequencing using surgically resected formalin-fixed, paraffin-embedded tissue.

Authors:  Tomoya Yokota; Masakuni Serizawa; Ayumu Hosokawa; Kimihide Kusafuka; Keita Mori; Toshiro Sugiyama; Yasuhiro Tsubosa; Yasuhiro Koh
Journal:  BMC Cancer       Date:  2018-08-16       Impact factor: 4.430

5.  PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome.

Authors:  Fernanda Franco Munari; Adriana Cruvinel-Carloni; Croider Franco Lacerda; Antônio Talvane Torres de Oliveira; Cristovam Scapulatempo-Neto; Sandra Regina Morini da Silva; Eduardo Crema; Sheila Jorge Adad; Maria Aparecida Marchesan Rodrigues; Maria Aparecida Coelho Arruda Henry; Denise Peixoto Guimarães; Adhemar Longatto-Filho; Rui Manuel Reis
Journal:  Infect Agent Cancer       Date:  2018-12-29       Impact factor: 2.965

6.  Genetic analysis of rapidly progressing esophageal squamous cell carcinoma: A case report.

Authors:  Shuang Zhao; Ni Sun; Xi Yuan; Zetian Shen; Xixu Zhu; Jing Li
Journal:  Medicine (Baltimore)       Date:  2021-03-05       Impact factor: 1.817

7.  PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.

Authors:  Lin Wang; Ling Shan; Shaokai Zhang; Jianming Ying; Liyan Xue; Yanling Yuan; Yongqiang Xie; Ning Lu
Journal:  PLoS One       Date:  2014-07-23       Impact factor: 3.240

8.  Subtype-specific overexpression of the Rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation.

Authors:  Laura Barrio-Real; Lorena G Benedetti; Nora Engel; Yaping Tu; Soonweng Cho; Saraswati Sukumar; Marcelo G Kazanietz
Journal:  Breast Cancer Res       Date:  2014-09-24       Impact factor: 6.466

9.  Antitumor Activity of Tenacissoside H on Esophageal Cancer through Arresting Cell Cycle and Regulating PI3K/Akt-NF-κB Transduction Cascade.

Authors:  Yong-Sen Jia; Xue-Qin Hu; Hegyi Gabriella; Li-Juan Qin; Nora Meggyeshazi
Journal:  Evid Based Complement Alternat Med       Date:  2015-09-30       Impact factor: 2.629

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.